Article info

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Authors

  1. Correspondence to Dr Brian I Rini; brian.rini{at}vumc.org
View Full Text

Citation

Rini BI, Signoretti S, Choueiri TK, et al
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Publication history

  • Accepted October 12, 2022
  • First published December 22, 2022.
Online issue publication 
December 22, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.